EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GLP-1 Receptor Agonists and Gout: A Narrative Review

Charlie Flint, Tony R. Merriman, Daniel H. Solomon

Gout, Urate, and Crystal Deposition Disease · 04.11.2026 · 4 (4) · 20

DOI: 10.3390/gucdd4040020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gout, Urate, and Crystal Deposition Disease, online erschienen am 04.11.2026. Verfasst von Charlie Flint und 2 weiteren Autor:innen. Die Arbeit nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide receptor agonists (GIP RAs) are incretin mimetics that have increased in use in the management of type 2 diabetes and obesity. Understanding the potential impact of incretin mimetics on gout is important because of their increased use and the relationship between obesity, insulin resistance, hyperuricemia, and gout. Current evidence supports that both metabolic and inflammatory pathways overlap between incretin mimetics and gout. Some data suggest a biphasic effect of GLP-1 RAs on gout risk—initially increasing gout flare risk and eventually decreasing flare risk, but this needs confirmation in larger prospective studies. The rapid weight loss that is seen on incretin mimetics may alter the renal handling of uric acid due to the presence of ketone bodies. However, sustained weight reduction and the direct inhibition of NF-κB signaling, reduced NLRP3 inflammasome activation, and alterations in macrophage polarization may reduce gout-related inflammation over the longer term. This narrative review aims to summarize the current understanding of the pharmacologic, metabolic, and immunologic mechanisms linking incretin mimetics with gout and aims to explore the potential implications for clinical management of gout.

Förderung

  • NIH

Zitieren

APA

Flint, C., Merriman, T. R., & Solomon, D. H. (2026). GLP-1 Receptor Agonists and Gout: A Narrative Review. Gout, Urate, and Crystal Deposition Disease, 4(4), 20. https://doi.org/10.3390/gucdd4040020

Vancouver

Flint C, Merriman TR, Solomon DH. GLP-1 Receptor Agonists and Gout: A Narrative Review. Gout, Urate, and Crystal Deposition Disease. 2026;4(4):20. doi:10.3390/gucdd4040020

BibTeX
@article{Flint2026,
  author = {Flint, Charlie and Merriman, Tony R. and Solomon, Daniel H.},
  title = {GLP-1 Receptor Agonists and Gout: A Narrative Review},
  journal = {Gout, Urate, and Crystal Deposition Disease},
  year = {2026},
  volume = {4},
  number = {4},
  pages = {20},
  doi = {10.3390/gucdd4040020}
}
Kostenlos starten →